Palvella Therapeutics (PVLA) Operating Income (QoQ) (2013 - 2026)

Palvella Therapeutics (PVLA) Operating Income (QoQ) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Palvella Therapeutics 318.78 Mn 56.92 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -31.41%
Dec 31, 2025 -11.07%
Sep 30, 2025 -10.02%
Jun 30, 2025 -17.52%
Mar 31, 2025 -80.28%
Dec 31, 2024 13.75%
Sep 30, 2024 -74.07%
Jun 30, 2024 -65.32%
Mar 31, 2024 -113.14%
Dec 31, 2023 213.37%
Sep 30, 2023 -672.32%
Jun 30, 2023 113.30%
Mar 31, 2023 -34.66%
Dec 31, 2022 5.33%
Sep 30, 2022 1.31%
Jun 30, 2022 -65.35%
Mar 31, 2022 32.20%
Dec 31, 2021 42.15%
Sep 30, 2021 -13.43%
Jun 30, 2021 -231.31%